{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:12:37Z","timestamp":1754485957078,"version":"3.40.5"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Nicosia and Yiannoukas Medical Laboratories\/ Bioiatriki Group"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Monitoring the levels of IgG antibodies against the SARS-CoV-2 is important during the coronavirus disease 2019 (COVID-19) pandemic, to plan an adequate and evidence-based public health response. After this study we report that the plasma levels of IgG antibodies against SARS-CoV-2 spike protein were higher in individuals with evidence of prior infection who received at least one dose of either an mRNA-based vaccine (Comirnaty BNT162b2\/Pfizer-BioNTech or Spikevax mRNA-1273\/Moderna) or an adenoviral-based vaccine (Vaxzervia ChAdOx1 nCoV-19 \/Oxford-Astra Zeneca) (n = 39) compared to i) unvaccinated individuals with evidence of prior infection with SARS-CoV-2 (n = 109) and ii) individuals without evidence of prior infection with SARS-CoV-2 who received one or two doses of one of the aforementioned vaccines (n = 342). Our analysis also revealed that regardless of the vaccine technology (mRNA-based and adenoviral vector-based) two doses achieved high anti- SARS-CoV-2 IgG responses. Our results indicate that vaccine-induced responses lead to higher levels of IgG antibodies compared to those produced following infection with the virus. Additionally, in agreement with previous studies, our results suggest that among individuals previously infected with SARS-CoV-2, even a single dose of a vaccine is adequate to elicit high levels of antibody response.<\/jats:p>","DOI":"10.1371\/journal.pone.0269885","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T17:34:37Z","timestamp":1655141677000},"page":"e0269885","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus"],"prefix":"10.1371","volume":"17","author":[{"given":"Christos","family":"Papaneophytou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andria","family":"Nicolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrtani","family":"Pieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Nicolaidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-7573","authenticated-orcid":true,"given":"Eleftheria","family":"Galatou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiannis","family":"Sarigiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markella","family":"Pantelidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlos","family":"Panayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theklios","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Stavraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenia","family":"Argyrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasos","family":"Kalogiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriacos","family":"Yiannoukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos C.","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-0037","authenticated-orcid":true,"given":"Kyriacos","family":"Felekkis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"7","key":"pone.0269885.ref001","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nat Med"},{"key":"pone.0269885.ref002","doi-asserted-by":"crossref","first-page":"633184","DOI":"10.3389\/fimmu.2021.633184","article-title":"Antibody responses in COVID-19: A review","volume":"12","author":"M Chvatal-Medina","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"pone.0269885.ref003","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19","volume":"383","author":"FJ Ibarrondo","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0269885.ref004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct early serological signatures track with SARS-CoV-2 survival","volume":"53","author":"C Atyeo","year":"2020","journal-title":"Immunity"},{"issue":"12","key":"pone.0269885.ref005","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jmcb\/mjaa070","article-title":"The development of neutralizing antibodies against SARS-CoV-2 and their common features","volume":"12","author":"LD Liu","year":"2020","journal-title":"J Mol Cell Biol"},{"issue":"52","key":"pone.0269885.ref006","doi-asserted-by":"crossref","first-page":"eabe5511","DOI":"10.1126\/sciimmunol.abe5511","article-title":"Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients","volume":"5","author":"B Isho","year":"2020","journal-title":"Sci Immunol"},{"issue":"52","key":"pone.0269885.ref007","article-title":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients","volume":"5","author":"AS Iyer","year":"2020","journal-title":"Sci Immunol"},{"key":"pone.0269885.ref008","first-page":"8","article-title":"Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination.","volume":"9","author":"H. Altawalah","year":"2021","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"pone.0269885.ref009","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","article-title":"Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19","volume":"12","author":"AK Wheatley","year":"2021","journal-title":"Nat Commun"},{"issue":"7851","key":"pone.0269885.ref010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"C Gaebler","year":"2021","journal-title":"Nature"},{"issue":"7","key":"pone.0269885.ref011","doi-asserted-by":"crossref","first-page":"e0254516","DOI":"10.1371\/journal.pone.0254516","article-title":"Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study","volume":"16","author":"M Risti\u0107","year":"2021","journal-title":"PLOS ONE"},{"key":"pone.0269885.ref012","article-title":"Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection","author":"F Gallais","year":"2021","journal-title":"Medrxiv"},{"issue":"17","key":"pone.0269885.ref013","first-page":"1695","article-title":"Loss of anti-SARS-CoV-2 antibodies mild Covid-19","volume":"383","author":"S Kutsuna","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0269885.ref014","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"QX Long","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"pone.0269885.ref015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/vaccines9050433","article-title":"An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times","volume":"9","author":"C Garc\u00eda-Montero","year":"2021","journal-title":"Vaccines"},{"key":"pone.0269885.ref016","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","author":"LM Dunkle","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0269885.ref017","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"NC Kyriakidis","year":"2021","journal-title":"npj Vaccines"},{"key":"pone.0269885.ref018","unstructured":"European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/covid-19-vaccines-studies-approval. Accessed 15 January 2022 ["},{"key":"pone.0269885.ref019","article-title":"Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.","author":"NM Clark","year":"2021","journal-title":"bioRxiv"},{"key":"pone.0269885.ref020","doi-asserted-by":"crossref","first-page":"101422","DOI":"10.1016\/j.smim.2020.101422","article-title":"The immunology of SARS-CoV-2 infections and vaccines","volume":"50","author":"L Grigoryan","year":"2020","journal-title":"Semin Immunol"},{"issue":"1","key":"pone.0269885.ref021","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s42003-020-01526-8","article-title":"The kinetics of humoral response and its relationship with the disease severity in COVID-19.","volume":"3","author":"L Ren","year":"2020","journal-title":"Commun Biol"},{"issue":"10","key":"pone.0269885.ref022","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41577-020-00436-4","article-title":"Not just antibodies: B cells and T cells mediate immunity to COVID-19","volume":"20","author":"RJ Cox","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"pone.0269885.ref023","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"J Seow","year":"2020","journal-title":"Nat Microbiol"},{"issue":"1","key":"pone.0269885.ref024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/pr800545q","article-title":"Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group","volume":"8","author":"MK Tuck","year":"2009","journal-title":"J Proteome Res"},{"issue":"1","key":"pone.0269885.ref025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/microorganisms10010085","article-title":"Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population","volume":"10","author":"G Krashias","year":"2022","journal-title":"Microorganisms"},{"issue":"24","key":"pone.0269885.ref026","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/jcm10245882","article-title":"Circulating IgG levels in SARS-CoV-2 convalescent individuals in Cyprus.","volume":"10","author":"I Mamais","year":"2021","journal-title":"J Clin Med"},{"issue":"19","key":"pone.0269885.ref027","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"IJ Amanna","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0269885.ref028","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41591-020-0895-3","article-title":"Modeling shield immunity to reduce COVID-19 epidemic spread","volume":"26","author":"JS Weitz","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"pone.0269885.ref029","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41591-020-0896-2","article-title":"Protecting the population with immune individuals","volume":"26","author":"OF Norheim","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"pone.0269885.ref030","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc070348","article-title":"Disappearance of antibodies to SARS-associated coronavirus after recovery","volume":"357","author":"W-C Cao","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0269885.ref031","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3201\/eid2307.170310","article-title":"MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015","volume":"23","author":"PG Choe","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"pone.0269885.ref032","article-title":"Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers","author":"X Guo","year":"2020","journal-title":"Medrxiv"},{"issue":"10","key":"pone.0269885.ref033","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3201\/eid1310.070576","article-title":"Duration of antibody responses after severe acute respiratory syndrome","volume":"13","author":"L-P Wu","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"pone.0269885.ref034","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3201\/eid2210.160706","article-title":"Persistence of antibodies against Middle East respiratory syndrome coronavirus","volume":"22","author":"DC Payne","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"pone.0269885.ref035","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"D Cromer","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"pone.0269885.ref036","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3390\/diagnostics11091709","article-title":"Antibodies against SARS-CoV-2 time course in patients and vaccinated subjects: An evaluation of the harmonization of two different methods","volume":"11","author":"R Dittadi","year":"2021","journal-title":"Diagnostics (Basel)."},{"issue":"7867","key":"pone.0269885.ref037","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Z Wang","year":"2021","journal-title":"Nature"},{"issue":"600","key":"pone.0269885.ref038","doi-asserted-by":"crossref","first-page":"eabi9915","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection.","volume":"13","author":"AJ Greaney","year":"2021","journal-title":"Sci Transl Med"},{"key":"pone.0269885.ref039","unstructured":"Cyprus Ministry of Health: https:\/\/www.pio.gov.cy\/coronavirus\/categories\/press. Accessed 18 January 2022"},{"issue":"6549","key":"pone.0269885.ref040","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"L Stamatatos","year":"2021","journal-title":"Science"},{"issue":"6549","key":"pone.0269885.ref041","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1126\/science.abh1282","article-title":"Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose","volume":"372","author":"CJ Reynolds","year":"2021","journal-title":"Science"},{"issue":"9","key":"pone.0269885.ref042","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom","volume":"6","author":"J Wei","year":"2021","journal-title":"Nat Microbiol"},{"issue":"6","key":"pone.0269885.ref043","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"QX Long","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"pone.0269885.ref044","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12916-021-02090-6","article-title":"Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and na\u00efve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients","volume":"19","author":"IP Trougakos","year":"2021","journal-title":"BMC Medicine"},{"issue":"1","key":"pone.0269885.ref045","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41598-021-82428-5","article-title":"Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan.","volume":"11","author":"Y Nakano","year":"2021","journal-title":"Sci Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T17:35:18Z","timestamp":1655141718000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269885"}},"subtitle":[],"editor":[{"given":"Tian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269885","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}